TARGET ALS FOUNDATION INC

Financials

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended December 31, 2025, highest compensation first.

Address and contacts

Address (IRS master file)

244 MADISON AVE 1025, NEW YORK, NY 10016-2817

Principal officer (990 for 2025)

KENNETH DEVANEY, 244 MADISON AVE 1025, NEW YORK, NY 10016

Signed the 990

KENNETH DEVANEY, TREASURER

Phone

(646) 592-2541

Website

TARGETALS.ORG

Return prepared by

KAHN LITWIN RENZA & CO LTD

Mission

OUR MISSION IS TO BREAK DOWN BARRIERS TO ALS RESEARCH TO FIND EFFECTIVE TREATMENTS. BY UNITING ACADEMIA, THE PHARMA AND BIOTECH INDUSTRY, GOVERNMENT, VENTURE CAPITAL, RELATED NONPROFITS, AND THE ALS COMMUNITY, WE AIM TO OVERCOME THE CHALLENGES THAT HAVE LONG HINDERED PROGRESS, BRINGING HOPE AND TANGIBLE ADVANCEMENTS TO THOSE AFFECTED BY THIS DEVASTATING DISEASE.

Program accomplishments

• RESEARCH WE FUND:TARGET ALS IS THE LARGEST AND MOST IMPACTFUL PRIVATE FUNDER OF ALS RESEARCH WORLDWIDE. THANKS TO THE GENEROUS TRUST PLACED IN US BY OUR DONORS, WE CAN DIRECT RESOURCES TO THE MOST PROMISING IDEAS AND EMERGING SCIENTIFIC LEADERS ACROSS THE GLOBE. OUR FUNDED PROJECTS HAVE A HIGH SUCCESS RATE, DELIVERING MEANINGFUL RESULTS TO ADVANCE IDEAS FROM EARLY TO LATE STAGE RESEARCH. IN 2025, WE CONTINUED TO EXPAND FUNDING OPPORTUNITIES, DRIVING NEARLY $12M INTO INNOVATION ACROSS 151 GRANTS IN THREE CRITICAL AREAS:UNDERSTANDING ALS BIOLOGY: ADVANCING INSIGHTS INTO THE ROOT CAUSES OF DISEASE TO IDENTIFY NEW DRUG TARGETS.ACCELERATING DRUG DISCOVERY: SUPPORTING PROOF-OF-CONCEPT STUDIES THAT PAVE THE WAY TOWARD CLINICAL TRIALS.DEVELOPING BIOMARKERS: ENABLING EARLIER DIAGNOSIS, IDENTIFYING ALS SUBTYPES, AND MONITORING DISEASE PROGRESSION WITH PRECISIONEVERY GRANT THAT TARGET ALS FUNDS IS TIED TO A DELIBERATE STRATEGY AND A LONG-RANGE VISION FOR THE FIELD, ENSURING THAT PROMISING IDEAS MOVE THROUGH THE FULL RESEARCH PATHWAY: UNCOVERING DISEASE BIOLOGY, IDENTIFYING AND REFINING NEW THERAPEUTIC TARGETS OR BIOMARKERS, VALIDATING THEM IN RIGOROUS MODELS, GENERATING TRANSLATIONAL DATA, AND PREPARING THE STRONGEST CANDIDATES FOR CLINICAL DEVELOPMENT. OUR FUNDING ALLOCATION REFLECTS WHERE THE STRONGEST IDEAS EMERGE. THE DISTRIBUTION OF OUR FUNDING ISN'T SET BY QUOTAS OR PERCENTAGES. IT'S SHAPED BY WHERE THE MOST COMPELLING SCIENCE IS HAPPENING. EACH YEAR, WE INVEST IN THE PROPOSALS WITH THE CLEAREST BIOLOGICAL RATIONALE, THE STRONGEST EVIDENCE, AND THE GREATEST POTENTIAL TO ADVANCE THE FIELD. RESEARCH WE ENABLE:TARGET ALS CONTINUES TO BREAK DOWN BARRIERS TO PROGRESS BY OFFERING NO-STRINGS-ATTACHED ACCESS TO CRITICAL TOOLS AND RESOURCES THROUGH OUR RESEARCH CORES. THESE SHARED RESOURCES ADDRESS LONGSTANDING CHALLENGES IN ALS RESEARCH THAT HAVE HISTORICALLY SLOWED DISCOVERY: LIMITED ACCESS, HIGH COSTS, AND LACK OF STANDARDIZATION. THE RESEARCH CORES ACCELERATE DRUG DISCOVERY AND BIOMARKER DEVELOPMENT WHILE FOSTERING COLLABORATION ACROSS THE GLOBAL ALS COMMUNITY. IN 2025, TARGET ALS INVESTED OVER $8M TO EMPOWER SCIENTISTS WITH THE MATERIALS, DATA, AND INFRASTRUCTURE THEY NEED TO DRIVE PROGRESS FROM THE BENCH TO THE CLINIC. FROM OUR POSTMORTEM TISSUE CORE TO THE LONGITUDINAL BIOFLUIDS CORE POWERED BY OUR GLOBAL NATURAL HISTORY STUDY (GNHS) AND OPEN-ACCESS DATA ENGINE, TARGET ALS PROVIDES RESEARCHERS WORLDWIDE WITH STATE-OF-THE-ART BIOSAMPLES, DATASETS, ANTIBODIES, AND MORE, WITH NO REACHTHROUGH ON INTELLECTUAL PROPERTY (IP). THESE TOOLS ARE AVAILABLE TO BOTH ACADEMIA AND INDUSTRY, ENSURING THAT SCIENTIFIC BREAKTHROUGHS CAN MOVE SWIFTLY AND COLLABORATIVELY TOWARD THERAPIES FOR PEOPLE LIVING WITH ALS. TO DATE, MORE THAN 1,750 PROJECTS HAVE RELIED ON THESE RESOURCES, SPANNING BASIC BIOLOGY, TARGET VALIDATION, BIOMARKER DISCOVERY, AND THERAPEUTIC DEVELOPMENT. AND THE MOMENTUM IS ONLY GROWING: OVER 500 RESEARCHERS HAVE ACCESSED OUR DATA ENGINE, WHILE GLOBAL CONSORTIA OF PREEMINENT SCIENTISTS ARE WORKING TOGETHER WITH TARGET ALS FUNDS TO SHARE DATA, REPLICATE FINDINGS, AND AMPLIFY IMPACT.RESEARCH WE CONDUCT:ALS IS A DISEASE THAT AFFECTS PEOPLE OF EVERY RACE AND ETHNICITY AROUND THE WORLD. HOWEVER, CLINICAL TRIALS ENROLL PRIMARILY PEOPLE OF WHITE, EUROPEAN DESCENT RESULTING IN A BIASED, INCOMPLETE VIEW OF DISEASE BIOLOGY ACROSS THE ALS GLOBAL POPULATION. THE ALS GLOBAL RESEARCH INITIATIVE (AGRI) IS THE ONLY COMPREHENSIVE, GLOBAL RESEARCH EFFORT THAT BRINGS TOGETHER TWO COMPLEMENTARY CLINICAL STUDIES DESIGNED TO UNCOVER THE CAUSES OF ALS AND IDENTIFY NEW BIOMARKERS THAT CAN DIAGNOSE THE DISEASE EARLIER, TRACK ITS PROGRESSION, AND PREDICT OUTCOMES. THESE STUDIES PROVIDE RESEARCHERS UNPRECEDENTED ACCESS TO PATIENT DATA AND BIOSAMPLES WORLDWIDE, RAPIDLY ACCELERATING NEW DISCOVERIES AND DRIVING PROGRESS TOWARD MORE EFFECTIVE THERAPIES. ULTIMATELY, INCLUSIVE RESEARCH STRENGTHENS SCIENTIFIC VALIDITY, IMPROVES PATIENT OUTCOMES, AND HELPS ENSURE THAT BREAKTHROUGHS BENEFIT EVERYONE, NOT JUST A SUBSET OF THE POPULATION. THROUGHOUT THE YEAR, WE INVESTED OVER $1.5M, WHICH FUELED AGRI'S BOLD GOAL: BRING THE WORLD TOGETHER TO TACKLE ALS FROM EVERY ANGLE. THROUGH OUR GLOBAL NATURAL HISTORY STUDY (GNHS) AND COMMUNITYBASED POP-UP CLINICS, WE'RE MAKING ALS RESEARCH MORE INCLUSIVE, MORE IMMEDIATE, AND MORE COLLABORATIVE THAN EVER BEFORE.
  Expenses $21,006,355 · grants $18,765,868

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

IRS record

EIN

81-0756743

Tax-exempt status

501(c)(3): Charitable, religious, educational or scientific organization

Foundation status

Publicly supported organization (170(b)(1)(A)(vi))

Donations deductible (Pub 78)

Public charity, 50% deduction limit

Exempt since

2020

Accounting year ends

December

Files

Form 990 or 990-EZ

Category (NTEE)

Education (B82)

Assets (IRS master file)

$136,912,637

Income (IRS master file)

$48,375,695

Filing history

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 81-0756743).

Questions about TARGET ALS FOUNDATION INC

What is the EIN of TARGET ALS FOUNDATION INC?

The employer identification number (EIN) of TARGET ALS FOUNDATION INC is 81-0756743.

Is TARGET ALS FOUNDATION INC tax-exempt?

Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2020.

Are donations to TARGET ALS FOUNDATION INC tax-deductible?

Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).

Which annual return does TARGET ALS FOUNDATION INC file?

Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.

When is the next return of TARGET ALS FOUNDATION INC due?

The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.

When did TARGET ALS FOUNDATION INC last file with the IRS?

The latest return in the IRS public files is the 990 for the year ended December 2025.

Who is the principal officer of TARGET ALS FOUNDATION INC?

The 990 for the year ended December 31, 2025 names KENNETH DEVANEY.

Who are the officers and directors of TARGET ALS FOUNDATION INC?

The 990 for the year ended December 31, 2025 lists 22 people; 8 received compensation from the organization, the highest $404,414 (MANISH RAISINGHANI, PRESIDENT).

How much revenue does TARGET ALS FOUNDATION INC have?

On its 990 for the year ended December 31, 2025 it reported revenue of $33,261,985, expenses of $25,618,714 and total assets of $136,912,637 at year end.

Other nonprofits in NEW YORK

• NEW YORK UNIVERSITY
  EIN 13-5562308 · last filed 990 for 2025
• TRUSTEES OF COLUMBIA UNIVERSITY
  EIN 13-5598093 · last filed 990 for 2025
• ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
  EIN 13-6171197 · last filed 990 for 2024
• CITY UNIVERSITY CONSTRUCTION FUND
  EIN 13-2587538 · last filed 990 for 2025
• COLLEGE BOARD
  EIN 13-1623965 · last filed 990 for 2024
• ANDREW W MELLON FOUNDATION
  EIN 13-1879954 · last filed 990-PF for 2024
• NYC SCHOOL SUPPORT SERVICES INC
  EIN 81-2621466 · last filed 990 for 2025
• AMERICAN UNIVERSITY OF BEIRUT
  EIN 13-5596846 · last filed 990 for 2025

All nonprofits in NEW YORK · New York · Education